Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036

GILEAD SCIENCES, INC. (GILD)

341
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

05/11/2012 | 03:06pm US/Eastern
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

React to this article
Latest news on GILEAD SCIENCES, INC.
3h ago GILEAD SCIENCES : Taps Philippe Bishop, MD as SVP, Hematology and Oncology Thera..
1d ago GILEAD SCIENCES : Presents Follow-up Data from Zydelig Registrational Studies in..
3d ago GILEAD SCIENCES : Philippe C. Bishop, MD, to Join Gilead as Senior Vice Presiden..
3d ago GILEAD SCIENCES : Assigned Patent
3d ago ZHEJIANG YONGTAI TECHNOLOGY : Yongtai Technology Invests in Sofosbuvir Mid-body
6d ago GILEAD SCIENCES : BetterInvesting Magazine Reveals Stock to Study and Undervalue..
6d ago GILEAD SCIENCES : BetterInvesting Magazine Posts February Stock To Study
6d ago GILEAD SCIENCES : GSK announces EU regulatory submission seeking extended indica..
7d ago GILEAD SCIENCES : Philadelphia Transportation Authority files lawsuit against Gi..
7d ago GILEAD SCIENCES : Releases Follow-up Data from Zydelig Registrational Studies
Advertisement
Chart
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF